Hologic, Inc. (HOLX) reported adjusted earnings per share (EPS) of $1.01 in the fourth quarter of fiscal 2024, up 13.5% year over year. However, the bottom line missed the Zacks Consensus Estimate by 0.9%.The adjustments include charges and benefits related to the amortization of acquired intangible assets, restructuring and integration/consolidation costs and many others.The company’s GAAP EPS was 76 cents in the quarter compared with 37 cents in the year-ago period.Fiscal 2024 adjusted EPS was $4.08, up 3 ...

Financial Data and Key Metrics Changes - Total revenue for Q4 2024 was $987.9 million, representing a 4.2% increase year-over-year, and 5% organic growth excluding COVID [32] - Non-GAAP earnings per share (EPS) for Q4 were $1.01, a 13.5% increase [32] - For the full fiscal year 2024, total revenue was $4.03 billion, a slight decline of 0.2%, but grew 5.3% organically excluding COVID [33] Business Line Data and Key Metrics Changes - Diagnostics revenue for Q4 was $443.3 million, growing 6.2%, and 9.2% organically excluding COVID [21] - Molecular Diagnostics grew 9.1% in Q4 and 9% for the full year, driven by BV/CV/TV assays [22] - Breast Health revenue for Q4 was $375.5 million, increasing 6.2% or 5.3% organically [25] - Surgical revenue for Q4 was $156.5 million, up 5.4% year-over-year [25] - Scalable business revenue decreased 54.9% to $12.7 million due to a temporary stop ship of Horizon DXA [26] Market Data and Key Metrics Changes - The international business has grown nearly 50% compared to 2019, with significant growth opportunities still available [27] - The company anticipates that international growth will outpace domestic growth in fiscal 2025 [74] Company Strategy and Development Direction - The company is focused on M&A strategies, having acquired Endomagnetics and planning to acquire Gynesonics, which align with its women's health focus [11][35] - Hologic aims to leverage its strong balance sheet for both organic growth initiatives and share repurchase programs [12][35] - The company is committed to advancing women's health globally and expects to deliver durable long-term results [49] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the business's ability to navigate transitory headwinds and expects accelerated revenue growth in the latter half of fiscal 2025 [65][66] - The company anticipates challenges in the first half of fiscal 2025 due to supply chain issues and strong prior year comparisons [40][66] - Management highlighted the importance of innovation and market creation as key drivers for future growth [16][18] Other Important Information - The company announced a new $250 million accelerated share repurchase program [12][35] - Gross margin for Q4 increased to 61.5%, up 110 basis points year-over-year [36] - Operating margins for Q4 finished at 30%, with net margin at 24% [38] Q&A Session Summary Question: Can you discuss the margin outlook for fiscal 2025? - Management indicated that transitory headwinds in the first half of the year would impact margins, but they expect improvements as these issues are resolved [52] Question: What is the outlook for the Breast Health business? - Management expects a slower growth rate in the Breast Health segment prior to the launch of new gantry products, but remains optimistic about existing products [54] Question: Can you provide sales figures for key growth drivers like Biotheranostics? - Management indicated that BV/CV/TV is expected to generate several hundred million dollars in revenue, while Biotheranostics is projected to be around $100 million [56] Question: What are the expectations for the international business growth? - Management expects international growth to outpace domestic growth in fiscal 2025 [74] Question: How is the company addressing the IV fluid shortage? - Management acknowledged the impact of the IV fluid shortage on surgical procedures and indicated it is a transitory issue [66] Question: Can you elaborate on the Gynesonics acquisition? - Management stated that Gynesonics complements the existing surgical portfolio and aligns with current procedures [62] Question: What is the expected impact of the skeletal stop ship on revenue? - Management estimated a loss of approximately $5 million per month due to the skeletal stop ship, with expectations to resume shipments in the latter half of Q1 [70]

For the quarter ended September 2024, Hologic (HOLX) reported revenue of $987.9 million, up 4.5% over the same period last year. EPS came in at $1.01, compared to $0.89 in the year-ago quarter.The reported revenue compares to the Zacks Consensus Estimate of $979.28 million, representing a surprise of +0.88%. The company delivered an EPS surprise of -0.98%, with the consensus EPS estimate being $1.02.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street ...

Hologic (HOLX) came out with quarterly earnings of $1.01 per share, missing the Zacks Consensus Estimate of $1.02 per share. This compares to earnings of $0.89 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of -0.98%. A quarter ago, it was expected that this medical device maker would post earnings of $1.02 per share when it actually produced earnings of $1.06, delivering a surprise of 3.92%.Over the last four quarters, the comp ...

Exhibit 99.1 Hologic Announces Financial Results for Fourth Quarter of Fiscal 2024 – Revenue of $987.9 Million, GAAP Diluted EPS of $0.76 and Non-GAAP Diluted EPS of $1.01 – – Total Company Revenue Growth of 4.5%, or 4.2% in Constant Currency and 5.0% Organically ex. COVID-19 in Constant Currency – – Company Expects Strong Execution of its Broad-Based Growth Strategy in Fiscal 2025 – MARLBOROUGH, Mass. (November 4, 2024) – Hologic, Inc. (Nasdaq: HOLX) announced today the Company's financial results for the ...

Analysts on Wall Street project that Hologic (HOLX) will announce quarterly earnings of $1.02 per share in its forthcoming report, representing an increase of 14.6% year over year. Revenues are projected to reach $979.28 million, increasing 3.6% from the same quarter last year. Over the past 30 days, the consensus EPS estimate for the quarter has been adjusted downward by 2.2% to its current level. This demonstrates the covering analysts' collective reassessment of their initial projections during this peri ...

In the latest trading session, Hologic (HOLX) closed at $80.46, marking a -0.46% move from the previous day. The stock trailed the S&P 500, which registered a daily gain of 0.27%. Meanwhile, the Dow experienced a rise of 0.65%, and the technology-dominated Nasdaq saw an increase of 0.26%. Shares of the medical device maker have appreciated by 0.01% over the course of the past month, outperforming the Medical sector's loss of 4.14% and lagging the S&P 500's gain of 2%. The investment community will be paying ...

Hologic, Inc.'s (HOLX) Diagnostics segment, excluding COVID-19 assay and related revenues, is expected to have significantly benefited from the robust Panther utilization in its Molecular Diagnostics franchise. Higher gantry deliveries and robust service revenues are likely to have contributed to the Breast Health segment's performance. Furthermore, MyoSure is likely to have emerged as the key driver of the GYN Surgical division's revenues. We anticipate that the company's fiscal 2024 fourth-quarter financi ...

Hologic (HOLX) closed at $81.15 in the latest trading session, marking a -0.51% move from the prior day. This move lagged the S&P 500's daily loss of 0.18%. Elsewhere, the Dow saw a downswing of 0.8%, while the techheavy Nasdaq appreciated by 0.27%. Coming into today, shares of the medical device maker had gained 0.22% in the past month. In that same time, the Medical sector lost 3.03%, while the S&P 500 gained 4.46%. The upcoming earnings release of Hologic will be of great interest to investors. The compa ...

Hologic (HOLX) is set to release fourth-quarter fiscal 2024 results on Nov. 4 after the closing bell.Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.The Zacks Consensus Estimate for fourth-quarter earnings suggests a 14.6% increase year over year to $1.02 per share. The estimate has remained stable in the past 60 days. The Zacks Consensus Estimate for fourth-quarter revenues currently stands at $979.3 million, a 3.6% improvement compared to the last year.Image Source: Zacks Investme ...